Neuroprotective effects of salvianolic acid B on an Aβ25-35 peptide-induced mouse model of Alzheimer's disease

Eur J Pharmacol. 2013 Mar 15;704(1-3):70-7. doi: 10.1016/j.ejphar.2013.02.015. Epub 2013 Feb 24.

Abstract

Salvianolic acid B (SalB) is a polyphenolic compound found in Salvia miltiorrhiza Bunge that has several anti-oxidative and anti-inflammatory effects. In the present study, we investigated whether SalB has neuroprotective effects in an amyloid β (Aβ) peptide-induced Alzheimer's disease mouse model. Mice were injected with Aβ25-35 peptide intracerebroventricularly and were subsequently administered SalB once daily for 7 days. Subchronic SalB administration (10mg/kg) significantly ameliorated the Aβ25-35 peptide-induced memory impairment in the passive avoidance task (P<0.05). SalB treatment also reduced the number of activated microglia and astrocytes that were observed during the inflammatory reaction after the administration of the Aβ25-35 peptide. Moreover, SalB markedly reduced inducible nitric oxide synthase and cyclooxygenase-2 expression levels and thiobarbituric acid reactive substances, which were increased by the administration of the Aβ25-35 peptide. Furthermore, SalB administration significantly rescued the Aβ25-35 peptide-induced decrease of choline acetyltransferase and brain-derived neurotrophic factor protein levels. These results suggest that SalB exerts neuroprotective activity via anti-inflammatory and anti-oxidative effects and that SalB may be a potential candidate for Alzheimer's disease therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / physiopathology
  • Amyloid beta-Peptides
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Avoidance Learning / drug effects
  • Behavior, Animal / drug effects
  • Benzofurans / pharmacology
  • Benzofurans / therapeutic use*
  • Brain-Derived Neurotrophic Factor / metabolism
  • Choline O-Acetyltransferase / metabolism
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / metabolism
  • Cognition Disorders / physiopathology
  • Cyclooxygenase 2 / metabolism
  • Disease Models, Animal
  • Hippocampus / cytology
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Lipid Peroxidation / drug effects
  • Male
  • Mice
  • Mice, Inbred ICR
  • Neuroglia / drug effects
  • Neuroglia / metabolism
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Nitric Oxide Synthase Type II / metabolism
  • Peptide Fragments

Substances

  • Amyloid beta-Peptides
  • Anti-Inflammatory Agents
  • Benzofurans
  • Brain-Derived Neurotrophic Factor
  • Neuroprotective Agents
  • Peptide Fragments
  • amyloid beta-protein (25-35)
  • salvianolic acid B
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • Choline O-Acetyltransferase